|
| General Information |
| Business: |
We are a biotechnology company that is developing innovative and proprietary treatments for nocturnal leg cramps and spasms associated with severe neuromuscular conditions. Our founders' novel insights regarding neuromuscular physiology form the basis of our development efforts. We believe that activation of certain receptors in primary sensory neurons reduces the repetitive firing, or hyperexcitability, of alpha-motor neurons, thereby preventing or reducing the frequency and intensity of muscle cramps and spasms. We also believe that we are the only company developing products based on this mechanism of muscle cramp inhibition. We have conducted three randomized, blinded, placebo-controlled cross-over studies of our proprietary treatment, which have shown a statistically significant reduction in the intensity of muscle cramps induced in healthy normal volunteers. |
|
| Industry: |
PHARMACEUTICAL PREPARATIONS |
|
| Employees: |
14 |
Founded: |
2014 |
|
| Contact Information |
| Address: |
800 Boylston Street, 24th Floor, Boston, MA 02199, US |
|
|
|
|
|
|
|
| Financial Information |
| |
| Revenues: |
$ 0.0 mil (last 12 months) |
|
| Net Income: |
$ -4.3 mil (last 12 months) |
|
| IPO Profile |
| Symbol: |
FLKS |
| Shares (millions): |
5.4 |
| Price Range: |
$16.00 - $16.00 |
| Est.$ Volume |
$ 84.6 mil |
| Manager / Joint Managers |
Jefferies/ Piper Jaffray |
| Co Managers |
JMP Securities/ Cantor Fitzgerald/ Roth Capital Partners |
| Expected to Trade |
1/29/2015 |
| Status |
Priced |
| SCOOP RATING |
Available only to Subscribers |
| RATING CHANGE |
Available only to Subscribers |
|
|
|
|
